ChoA Pharmaceutical Co.Ltd (034940) fair value: what the stock is really worth
As of Sep 29, 2026: fair value of ChoA Pharmaceutical Co.Ltd KRW 529, price KRW 2,620, upside -79.8%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ChoA Pharmaceutical Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2,525 KRW – 25,150 KRW · fair‑value band 394.70 KRW – 789.41 KRW · the 2,620 KRW price screens above the 528.90 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow ChoA Pharmaceutical Co.Ltd in your weekly email
Every Wednesday you see whether ChoA Pharmaceutical Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc.
Show more
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral nervous system; gynecologic diseases; antibiotics, antigens, and anthelmintic; and antitumor, as well as other metabolite medicines. The company offers its products in the form of tablets, capsules, granules, syrups, solutions, drinkable ampoules, and sachets. It also provides medicine supply and pharmacy management services. The company exports its products to approximately 20 countries worldwide. The company was founded in 1964 and is headquartered in Seoul, South Korea.
Stock analysis
ChoA Pharmaceutical Co.Ltd (034940) currently trades at 2,620 KRW, while our model-based Fair Value estimate is 528.90 KRW, 79.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the evidence level at low.
Scenario range: 394.70 KRW (bear) to 789.41 KRW (bull), the price of 2,620 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
ChoA Pharmaceutical Co.Ltd reported revenue of 59.3B KRW in FY2025 versus 57.6B KRW in FY2021, a compound +0.8%/yr. Reported net income was −6.8B KRW in FY2025.
Key figures
Market cap 22.0B KRW (≈ $16.2M) · P/S ratio 0.37 · Net margin −11.5% · Return on equity −22.1% · Return on assets (EBIT) −9.5% · Operating margin −7.6% · Revenue (TTM) 59.6B KRW · Revenue growth (YoY) +2.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).
What moves the price
The share trades about 55% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −80%, 034940 screens richer than that median.
Fair Value models
Bear 394.70 KRWFair Value 528.90 KRWBull 789.41 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Start year 2020 (pandemic). Over 10 years: +1.7% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4.2% (2020) → −11.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare ChoA Pharmaceutical Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 624 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside−79.8% · Bottom 25%
Profitability
Return on assets−5.4% · Bottom 25%
Net margin (TTM)−7.9% · Bottom 25%
Operating margin (TTM)−7.6% · Bottom 25%
Growth and dividend
Revenue growth2.1% · Below median
Balance sheet
Debt / equity0.08× · Below median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)11· sector 18
PAST (return on equity)0· sector 25
HEALTH (low debt)96· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ChoA Pharmaceutical Co.Ltd (034940) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 528.90 KRW versus a price of 2,620 KRW, about −80% upside (overvalued).
What is the fair value of 034940?
Our model-based fair value for ChoA Pharmaceutical Co.Ltd is 528.90 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,620 KRW.
What is the quality score of 034940?
ChoA Pharmaceutical Co.Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ChoA Pharmaceutical Co.Ltd (034940)?
Our model-based price target is the fair value of 528.90 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 394.70 KRW, optimistic scenario 789.41 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ChoA Pharmaceutical Co.Ltd stock forecast for 2026?
Our models put fair value at 528.90 KRW, about −80% upside versus a price of 2,620 KRW (overvalued). Cautious scenario 394.70 KRW, optimistic scenario 789.41 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ChoA Pharmaceutical Co.Ltd (034940)?
ChoA Pharmaceutical Co.Ltd reported trailing-twelve-month revenue of about 59.6B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ChoA Pharmaceutical Co.Ltd (034940)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ChoA Pharmaceutical Co.Ltd it is 528.90 KRW per share (as of Sep 24, 2026), against a price of 2,620 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ChoA Pharmaceutical Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 034940 trades above its calculated fair value: price 2,620 KRW, fair value 528.90 KRW, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 034940?
No. The price is what the market pays today (2,620 KRW); the fair value is what the company's own numbers justify (528.90 KRW). For ChoA Pharmaceutical Co.Ltd the two are 2,091 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ChoA Pharmaceutical Co.Ltd worth?
The market values ChoA Pharmaceutical Co.Ltd at about 22.0B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,620 KRW; our models calculate a fair value of 528.90 KRW per share.
What do the bullish and bearish scenarios say about 034940?
Our models span a range for ChoA Pharmaceutical Co.Ltd: cautious scenario 394.70 KRW, base 528.90 KRW, optimistic 789.41 KRW per share (as of Sep 24, 2026, price 2,620 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ChoA Pharmaceutical Co.Ltd (034940)?
Balance-sheet figures for ChoA Pharmaceutical Co.Ltd (as of Sep 24, 2026): return on equity −22.1%, debt of 0.08 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 034940 from its 52-week high?
ChoA Pharmaceutical Co.Ltd trades at 2,620 KRW, about 55% below its 52-week high of 5,800 KRW and 4% above the low of 2,525 KRW (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of 528.90 KRW is for.
Which stocks are comparable to ChoA Pharmaceutical Co.Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ChoA Pharmaceutical Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 2,620 KRW, calculated fair value 528.90 KRW (−80%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 034940 calculated?
We run ChoA Pharmaceutical Co.Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 528.90 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. ChoA Pharmaceutical Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ChoA Pharmaceutical Co.Ltd (034940)?
The closing price on Sep 29, 2026 was 2,620 KRW. Our model-based fair value is 528.90 KRW, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ChoA Pharmaceutical Co.Ltd right now?
The price sits above even our optimistic bull case (789.41 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (394.70 KRW to 789.41 KRW) leaves room in how you read the outcome.
Key figures of ChoA Pharmaceutical Co.Ltd
How large is the market capitalisation of ChoA Pharmaceutical Co.Ltd (034940)?
The market capitalisation of ChoA Pharmaceutical Co.Ltd is 22.0B KRW (≈ $16.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ChoA Pharmaceutical Co.Ltd (034940)?
The price-to-sales ratio of ChoA Pharmaceutical Co.Ltd is 0.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ChoA Pharmaceutical Co.Ltd (034940)?
The net margin of ChoA Pharmaceutical Co.Ltd is −11.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ChoA Pharmaceutical Co.Ltd (034940)?
The return on equity (ROE) of ChoA Pharmaceutical Co.Ltd is −22.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ChoA Pharmaceutical Co.Ltd (034940)?
On an EBIT basis the return on assets of ChoA Pharmaceutical Co.Ltd is −9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ChoA Pharmaceutical Co.Ltd (034940)?
The operating margin of ChoA Pharmaceutical Co.Ltd is −7.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ChoA Pharmaceutical Co.Ltd (034940)?
Revenue at ChoA Pharmaceutical Co.Ltd is growing +2.1% versus a year earlier (3y avg −4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ChoA Pharmaceutical Co.Ltd (034940)?
Earnings per share at ChoA Pharmaceutical Co.Ltd are growing +360% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ChoA Pharmaceutical Co.Ltd (034940) generate?
The free cash flow of ChoA Pharmaceutical Co.Ltd is −5.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ChoA Pharmaceutical Co.Ltd (034940) carry?
The net debt of ChoA Pharmaceutical Co.Ltd is 22.7B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ChoA Pharmaceutical Co.Ltd in the live analysis
One click puts ChoA Pharmaceutical Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
